Other Drug Names:

mTOR inhibitors (epithelial stem cell loss/mucositis/head and neck squamous cell carcinoma), National Institute of Dental and Craniofacial Research; rapamycin and analogs (head and neck squamous cell carcinoma), NIDCR

---

Technologies

Small molecule therapeutic; Systemic formulation unspecified

---

Development Status (Current)

National Institute of Dental and Craniofacial Research: US: Discovery: Mucositis: 05-Sep-2012 National Institutes of Health: US: Discovery: Mucositis: 05-Sep-2012 National Institute of Dental and Craniofacial Research: US: Discovery: Alopecia: 05-Sep-2012 National Institutes of Health: US: Discovery: Alopecia: 05-Sep-2012 National Institute of Dental and Craniofacial Research: US: Phase 2 Clinical: Head and neck tumor: 31-Aug-2010 National Institutes of Health: US: Phase 2 Clinical: Head and neck tumor: 31-Aug-2010

---

Development Status (History)

---

Drug Development Phase

[Mucositis: Discovery: US Mucositis: Discovery: US Alopecia: Discovery: US Alopecia: Discovery: US Head and neck tumor: Phase 2 Clinical: US Head and neck tumor: Phase 2 Clinical: US]

---

Therapy Area:

Dermatologic; Gastrointestinal; Cancer

Highest Status

Phase 2 Clinical

Target-based Actions

mTOR inhibitor

Other Actions

Anticancer

Active Indications

Alopecia; Head and neck tumor; Mucositis